schliessen

Filtern

 

Bibliotheken

The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line

Cisplatin is the mainstay of treatment for advanced bladder cancer. However, intrinsic or acquired resistance to cisplatin is common, which severely limits its therapeutic potential. We determined the synergistic antitumor effect of cisplatin and the histone deacetylase inhibitor trichostatin A in c... Full description

Journal Title: The Journal of Urology 2011, Vol.185(3), pp.1102-1111
Main Author: Yoon, Cheol Yong
Other Authors: Park, Mi Jung , Lee, Jung Sun , Lee, Sang Chul , Oh, Jong Jin , Park, Hongzoo , Chung, Chang Wook , Abdullajanov, Murod M , Jeong, Seong Jin , Hong, Sung Kyu , Byun, Seok Soo , Lee, Eun Sik , Lee, Sang Eun
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-5347 ; E-ISSN: 1527-3792 ; DOI: 10.1016/j.juro.2010.10.034
Link: https://www.sciencedirect.com/science/article/pii/S002253471004913X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_juro_2010_10_034
title: The Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line
format: Article
creator:
  • Yoon, Cheol Yong
  • Park, Mi Jung
  • Lee, Jung Sun
  • Lee, Sang Chul
  • Oh, Jong Jin
  • Park, Hongzoo
  • Chung, Chang Wook
  • Abdullajanov, Murod M
  • Jeong, Seong Jin
  • Hong, Sung Kyu
  • Byun, Seok Soo
  • Lee, Eun Sik
  • Lee, Sang Eun
subjects:
  • Urinary Bladder
  • Carcinoma
  • Cisplatin
  • Histone Deacetylase Inhibitors
  • Trichostatin A
  • Medicine
ispartof: The Journal of Urology, 2011, Vol.185(3), pp.1102-1111
description: Cisplatin is the mainstay of treatment for advanced bladder cancer. However, intrinsic or acquired resistance to cisplatin is common, which severely limits its therapeutic potential. We determined the synergistic antitumor effect of cisplatin and the histone deacetylase inhibitor trichostatin A in cisplatin resistant human bladder cancer cells. The cisplatin resistant human bladder cancer cell line T24R2 was exposed to cisplatin and/or trichostatin A. Tumor cell proliferation was examined by cell counting kit assay. Synergism between 2 drugs was examined by the combination index. Changes in cell cycle and apoptosis were determined by flow cytometry. We analyzed the expression of caspase-3, 8 and 9, poly(adenosine diphosphate-ribose) polymerase, p21 , cyclin A, B1 and D1, Cdc2c, p-Cdc2c, Cdc25c, p-Cdc25c, cytochrome c, p-Akt, t-Akt, Bcl-2, Bax, Bad, vascular endothelial growth factor and fetal liver kinase-1 by Western blot and colorimetric...
language: eng
source:
identifier: ISSN: 0022-5347 ; E-ISSN: 1527-3792 ; DOI: 10.1016/j.juro.2010.10.034
fulltext: fulltext
issn:
  • 0022-5347
  • 00225347
  • 1527-3792
  • 15273792
url: Link


@attributes
ID425112728
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_juro_2010_10_034
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_juro_2010_10_034
sourcesystemPC
dbid
0--K
11B1
21P~
3457
44G.
57-5
6AAEDT
7AAQFI
8ADPAM
9AEVXI
10AGHFR
11AITUG
12ALXNB
13BELOY
14FDB
15FGOYB
16GBLVA
17KOM
18R2-
19RPZ
20SEL
21SES
22SSZ
23UV1
24XH2
pqid851752342
galeid249161006
display
typearticle
titleThe Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line
creatorYoon, Cheol Yong ; Park, Mi Jung ; Lee, Jung Sun ; Lee, Sang Chul ; Oh, Jong Jin ; Park, Hongzoo ; Chung, Chang Wook ; Abdullajanov, Murod M ; Jeong, Seong Jin ; Hong, Sung Kyu ; Byun, Seok Soo ; Lee, Eun Sik ; Lee, Sang Eun
ispartofThe Journal of Urology, 2011, Vol.185(3), pp.1102-1111
identifier
subjectUrinary Bladder ; Carcinoma ; Cisplatin ; Histone Deacetylase Inhibitors ; Trichostatin A ; Medicine
descriptionCisplatin is the mainstay of treatment for advanced bladder cancer. However, intrinsic or acquired resistance to cisplatin is common, which severely limits its therapeutic potential. We determined the synergistic antitumor effect of cisplatin and the histone deacetylase inhibitor trichostatin A in cisplatin resistant human bladder cancer cells. The cisplatin resistant human bladder cancer cell line T24R2 was exposed to cisplatin and/or trichostatin A. Tumor cell proliferation was examined by cell counting kit assay. Synergism between 2 drugs was examined by the combination index. Changes in cell cycle and apoptosis were determined by flow cytometry. We analyzed the expression of caspase-3, 8 and 9, poly(adenosine diphosphate-ribose) polymerase, p21 , cyclin A, B1 and D1, Cdc2c, p-Cdc2c, Cdc25c, p-Cdc25c, cytochrome c, p-Akt, t-Akt, Bcl-2, Bax, Bad, vascular endothelial growth factor and fetal liver kinase-1 by Western blot and colorimetric...
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S002253471004913X$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Yoon, Cheol Yong
1Park, Mi Jung
2Lee, Jung Sun
3Lee, Sang Chul
4Oh, Jong Jin
5Park, Hongzoo
6Chung, Chang Wook
7Abdullajanov, Murod M
8Jeong, Seong Jin
9Hong, Sung Kyu
10Byun, Seok Soo
11Lee, Eun Sik
12Lee, Sang Eun
titleThe Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line
description

Cisplatin is the mainstay of treatment for advanced bladder cancer. However, intrinsic or acquired resistance to cisplatin is common, which severely limits its therapeutic potential. We determined the synergistic antitumor effect of cisplatin and the histone deacetylase inhibitor trichostatin A in cisplatin resistant human bladder cancer cells.

The cisplatin resistant human bladder cancer cell line T24R2 was exposed to cisplatin and/or trichostatin A. Tumor cell proliferation was examined by cell counting kit assay. Synergism between 2 drugs was examined by the combination index. Changes in cell cycle and apoptosis were determined by flow cytometry. We analyzed the expression of caspase-3, 8 and 9, poly(adenosine diphosphate-ribose) polymerase, p21

, cyclin A, B1 and D1, Cdc2c, p-Cdc2c, Cdc25c, p-Cdc25c, cytochrome c, p-Akt, t-Akt, Bcl-2, Bax, Bad, vascular endothelial growth factor and fetal liver kinase-1 by Western blot and colorimetric...

subject
0Urinary Bladder
1Carcinoma
2Cisplatin
3Histone Deacetylase Inhibitors
4Trichostatin A
5Medicine
general
0English
1Elsevier Inc
210.1016/j.juro.2010.10.034
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_juro_2010_10_034
issn
00022-5347
100225347
21527-3792
315273792
rsrctypearticle
creationdate2011
addtitleThe Journal of Urology
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
11B1
21P~
3457
44G.
57-5
6AAEDT
7AAQFI
8ADPAM
9AEVXI
10AGHFR
11AITUG
12ALXNB
13BELOY
14FDB
15FGOYB
16GBLVA
17KOM
18R2-
19RPZ
20SEL
21SES
22SSZ
23UV1
24XH2
startdate20110101
enddate20111231
lsr40The Journal of Urology, 2011, Vol.185 (3), pp.1102-1111
doi10.1016/j.juro.2010.10.034
citationpf 1102 pt 1111 vol 185 issue 3
lsr30VSR-Enriched:[galeid, pqid]
sort
titleThe Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line
authorYoon, Cheol Yong ; Park, Mi Jung ; Lee, Jung Sun ; Lee, Sang Chul ; Oh, Jong Jin ; Park, Hongzoo ; Chung, Chang Wook ; Abdullajanov, Murod M ; Jeong, Seong Jin ; Hong, Sung Kyu ; Byun, Seok Soo ; Lee, Eun Sik ; Lee, Sang Eun
creationdate20110000
lso0120110000
facets
frbrgroupid3285799418834646135
frbrtype5
newrecords20190904
languageeng
topic
0Urinary Bladder
1Carcinoma
2Cisplatin
3Histone Deacetylase Inhibitors
4Trichostatin A
5Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Yoon, Cheol Yong
1Park, Mi Jung
2Lee, Jung Sun
3Lee, Sang Chul
4Oh, Jong Jin
5Park, Hongzoo
6Chung, Chang Wook
7Abdullajanov, Murod M
8Jeong, Seong Jin
9Hong, Sung Kyu
10Byun, Seok Soo
11Lee, Eun Sik
12Lee, Sang Eun
jtitleJournal of Urology
creationdate2011
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Yoon
1Park
2Lee
3Oh
4Chung
5Abdullajanov
6Jeong
7Hong
8Byun
aufirst
0Cheol Yong
1Mi Jung
2Jung Sun
3Sang Chul
4Jong Jin
5Hongzoo
6Chang Wook
7Murod M
8Seong Jin
9Sung Kyu
10Seok Soo
11Eun Sik
12Sang Eun
auinitC
auinit1C
au
0Yoon, Cheol Yong
1Park, Mi Jung
2Lee, Jung Sun
3Lee, Sang Chul
4Oh, Jong Jin
5Park, Hongzoo
6Chung, Chang Wook
7Abdullajanov, Murod M
8Jeong, Seong Jin
9Hong, Sung Kyu
10Byun, Seok Soo
11Lee, Eun Sik
12Lee, Sang Eun
atitleThe Histone Deacetylase Inhibitor Trichostatin A Synergistically Resensitizes a Cisplatin Resistant Human Bladder Cancer Cell Line
jtitleThe Journal of Urology
date2011
risdate2011
volume185
issue3
spage1102
epage1111
pages1102-1111
issn0022-5347
eissn1527-3792
formatjournal
genrearticle
ristypeJOUR
abstract

Cisplatin is the mainstay of treatment for advanced bladder cancer. However, intrinsic or acquired resistance to cisplatin is common, which severely limits its therapeutic potential. We determined the synergistic antitumor effect of cisplatin and the histone deacetylase inhibitor trichostatin A in cisplatin resistant human bladder cancer cells.

The cisplatin resistant human bladder cancer cell line T24R2 was exposed to cisplatin and/or trichostatin A. Tumor cell proliferation was examined by cell counting kit assay. Synergism between 2 drugs was examined by the combination index. Changes in cell cycle and apoptosis were determined by flow cytometry. We analyzed the expression of caspase-3, 8 and 9, poly(adenosine diphosphate-ribose) polymerase, p21

, cyclin A, B1 and D1, Cdc2c, p-Cdc2c, Cdc25c, p-Cdc25c, cytochrome c, p-Akt, t-Akt, Bcl-2, Bax, Bad, vascular endothelial growth factor and fetal liver kinase-1 by Western blot and colorimetric...

pubElsevier Inc
doi10.1016/j.juro.2010.10.034
lad01The Journal of Urology